For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary
Tokyo, Japan (June 16, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that on June 17, 2016, its generics subsidiary, Daiichi Sankyo Espha, will launch eleven new generic drugs with four new active ingredients, which have been notified through today’s official gazette.
Overview
1. Product Names/Therapeutic Categories
|
Product name
|
Therapeutic category
|
Original brand name
|
|
Olanzapine Tablets 2.5mg “DSEP”
|
Antipsychotic
|
Zyprexa® Tablets
2.5mg, 5mg, 10mg
Zyprexa® Fine Granule 1%
Zyprexa Zydis® Tablets
2.5mg, 5mg, 10mg
|
|
Olanzapine Tablets 5mg “DSEP”
|
|
Olanzapine Tablets 10mg “DSEP”
|
|
Olanzapine Fine Granule 1% “DSEP”
|
|
Olanzapine OD Tablets 2.5mg “DSEP”
|
|
Olanzapine OD Tablets 5mg “DSEP”
|
|
Olanzapine OD Tablets10mg “DSEP”
|
|
Voriconazole Tablets 50mg “DSEP”
|
Systemic mycoses therapy
|
Vfend® Tablets
50mg, 200mg
|
|
Voriconazole Tablets 200mg “DSEP”
|
|
Sertraline Tablets 100mg “DSEP”
|
Selective serotonin reuptake inhibitor
|
J Zoloft® Tablets 100mg
|
|
Losarhyd® Combination Tablets HD “EP”
|
ARB/diuretic combination
|
Preminent® Combination Tablets HD
|
*Sertraline Tablets 100mg “DSEP” and Losarhyd® Combination Tablets HD “EP” are additional strengths for the same compounds currently on the market.
2. Product Attributes – Daiichi Sankyo Espha Measures
Daiichi Sankyo Espha has maintained a level of quality based on the quality management standards of the Daiichi Sankyo Group to meet the various needs of patients and health care professionals. Daiichi Sankyo Espha provides innovative high value-added generic drugs with formulation and labeling which make drugs easier for patients to ingest and harder to mistakenly or incorrectly take. It also provides authorized generics which are manufactured from the same substances and additives that are manufactured in the same manufacturing methods as original drugs.
Innovative design of Press Through Package (PTP) Sheets and Tablets
Ongoing innovations in formulation and labeling reduce the burden on pharmacists when confirming and preventing drug error and prevent medical error, such as patients taking the wrong medicine or confusing one medicine for another.
・Easily recognizable original symbols:
PTP sheets feature original symbols based on formulation and disease characteristics.
Olanzapine Tablets 10mg “DSEP” and Voriconazole Tablets 50mg “DSEP” original symbols
・Other PTP sheet innovations:
To reduce drug error, PTP sheets include GS1 codes on the back of each tablet sheet. Pitch control is used to print product names and strength in same position on the PTP sheet for each tablet, making displayed content easier to read.
・Double-sided printing (Laser and ink-jet printing):
Double-sided Printing of Product Name, Strength for Easier Identification.
Innovative Box Design－Introducing the Newly Designed “iPackage” Box
・Newly devised box display allows pharmacists to identify a variety of information.
About Daiichi Sankyo Espha
Daiichi Sankyo Espha manufactures and markets generic drugs and accommodates rising demand based on the spirit of the Daiichi Sankyo Group corporate philosophy* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.
*Daiichi Sankyo Group corporate philosophy
To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.
Daiichi Sankyo Espha Company Overview
Company name: Daiichi Sankyo Espha Co., Ltd.
Established: April 1, 2010
Business: Manufacture and sale of pharmaceuticals
Capital: 450 million yen
Representative: President Hiroto Yoshiwaka
Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo